| __timestamp | Axsome Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 59644696 |
| Thursday, January 1, 2015 | 2419289 | 79541000 |
| Friday, January 1, 2016 | 6343648 | 98015000 |
| Sunday, January 1, 2017 | 7206691 | 103958000 |
| Monday, January 1, 2018 | 9351522 | 103654000 |
| Tuesday, January 1, 2019 | 13598030 | 128951000 |
| Wednesday, January 1, 2020 | 28896749 | 135799000 |
| Friday, January 1, 2021 | 66646205 | 149883000 |
| Saturday, January 1, 2022 | 159253661 | 220206000 |
| Sunday, January 1, 2023 | 323123000 | 265542000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Axsome Therapeutics, Inc. and Travere Therapeutics, Inc. have shown distinct strategies over the past decade. From 2014 to 2023, Axsome's SG&A expenses skyrocketed by over 23,000%, starting from a modest $1.4 million to a staggering $323 million. In contrast, Travere's expenses grew by 345%, reaching $266 million in 2023.
While both companies have increased their spending, Axsome's aggressive expansion strategy is evident. This could indicate a focus on rapid growth and market penetration. Travere, with a steadier increase, might be optimizing its resources more conservatively. Understanding these trends provides valuable insights into each company's operational strategies and their potential impact on future profitability.
AbbVie Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amgen Inc. and Axsome Therapeutics, Inc.: SG&A Spending Patterns Compared
Regeneron Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and Veracyte, Inc.
Axsome Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Axsome Therapeutics, Inc. vs Galapagos NV: SG&A Expense Trends
Rhythm Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?